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[57] ABSTRACT 
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serotonergic and/or adrenergic antagonists in combination 
With nicotinic and opioid agonists, anti-depressants, 
stimulants, non-steroidal anti-in?ammatory drugs, and local 
anesthetics, such combinations being useful in the treatment 
of excitable system disorders, pain and psychiatric disorders, 
and methods of use thereof. 
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COMBINED ANTAGONIST COMPOSITIONS 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Patent Application No. 60/050,557 ?led Jun. 23, 1997, 
Which is incorporated herein by reference. 
TECHNICAL FIELD 
The invention relates to pharmaceutical compositions for 
the treatment of excitable system disorders, including 
analgesics, anti-excitatory agents, anti-hyperalgesic agents, 
anti-depressant agents, anti-suffering agents, antisocial per 
sonality treatments, conduct disorder treatments, attention 
de?cit treatments and drug abuse treatments. The invention 
further relates to novel drug combinations of antagonists of 
excitable system cellular receptor systems and their methods 
of use in treating excitable system abnormalities, pain and 
psychiatric disorders. More particularly, the invention 
relates to compositions Which are combinations of nicotinic, 
opioid, serotonergic and adrenergic antagonists and uses 
thereof in the treatment of excitable system abnormalities. 
Exemplary of the compositions of the invention is a com 
bination of a therapeutically effective amount of the nico 
tinic antagonist mecamylamine and the opioid antagonist 
naltrexone. 
BACKGROUND ART 
There exists clinical and scienti?c evidence for excitatory 
and inhibitory processes Which contribute to excitable sys 
tem activity, pain and psychiatric disorders. The pharmaco 
logic actions of analgesic and anti-depressant agents pre 
scribed to counteract these disorders are thought to be 
elicited through interactions With endogenous receptors 
Which alter the activity of excitable systems. 
Excitable System Disorders 
Clinical depression is characteriZed by symptoms Which 
include failure to obtain pleasure from activities Which 
previously brought enjoyment. Similarly, individuals expe 
riencing difficulties With alcohol, tobacco, stimulants such as 
cocaine and narcotic analgesics such as heroin, have a 
depressive syndrome characteriZed by one or more of a poor 
self image, feelings of incompetence and/or inadequacies, 
alienation, unpopularity and the like. The pathologic feel 
ings of these depressed and/or drug dependent individuals 
have been collectively called “hypophoria,” and are mani 
fest by a general loss of pleasure and interest in most typical 
activities. Such hypophoric feelings are an essential feature 
of the persistent depressive state as described by the Ameri 
can Psychiatric Association. 
These same hypophoric feelings are also present in many 
adolescents and are particularly strong in those that have 
been diagnosed as having conduct disorders. Moreover, it is 
Well established that adolescence and early adulthood is a 
turbulent time in development When drug abuse, mood and 
behavior problems emerge. Thus, the lack of coping skills 
needed to cope With emerging needs in a socially acceptable 
manner and the ability of psychoactive drugs to decrease the 
associated discomfort have long been considered related. 
Most drugs of abuse, at least on a temporary basis, reverse 
depressive or hypophoric feelings—an attribute that is, at 
least in part, thought to be responsible for their reinforcing 
effects. For heroin, morphine and related drugs, barbiturates, 
amphetamine, cocaine and marijuana, this role for the anti 
hypophoric effect has been unequivocally demonstrated. 
When individuals use opioid drugs such as heroin, mor 
phine and the like, they soon become dependent and, upon 
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2 
WithdraWal, an abstinence syndrome emerges. Typically, 
such a syndrome is initially quite discomforting and in many 
Ways resembles a severe ?u-like illness, including chills, 
fever, heightened autonomic tone, and decreased caloric 
intake. This is folloWed by a chronic illness characteriZed by 
exaggerated responsiveness to stressful and painful stimuli 
and lessened tone of the autonomic nervous system. This 
latter phase has been called protracted or secondary absti 
nence. 
Associated With this increased responsiveness to pain are 
exaggerated feelings of tiredness, lack of energy and social 
WithdraWal, as Well as hypophoria. These symptoms are also 
common to many mood and behavior disorders. Thus, a 
cycle traps drug abusers and those individuals With mood 
and behavior disorders in a deepening condition of discon 
tent and hypophoria With a state of continuing vulnerability. 
Several studies concerned With the psychiatric pro?les of 
cocaine users have indicated that these patients may exhibit 
a range of other psychiatric disorders including depression, 
bipolar disorder, cyclothymia and attention de?cit disorders. 
Further, a variety of drugs of abuse, including morphine-like 
drugs, amphetamines and barbiturates, produce dose related 
increases on the Morphine-BenZedrine Group (MBG) scale 
Which measures feelings of Well being and contains items 
Which are polarly opposite to the items comprising the 
hypophoria scale of the Addiction Research Center Matu 
ration Scale (ARCMS). Cocaine’s subjective effects are very 
similar to the effects of amphetamines. 
These ?ndings support the hypothesis that many sub 
stance abusers have a depressive diathesis and that drugs of 
abuse provide at least temporary relief from these pre 
existing psychopathologies. HoWever, drugs of abuse may 
Worsen pre-existing psychopathologies and therefore further 
predispose individuals to diseases of pharmacologic adap 
tation and addiction. 
Although the ef?cacies of currently available anti 
depressant preparations are established, a number of promi 
nent problems exist With therapeutic use of these agents. For 
example, biological heterogeneity of even the most carefully 
diagnosed patients With depressive diatheses is a fundamen 
tal problem facing clinicians. Moreover, less than satisfac 
tory efficacy is a problem in a portion of this patient 
population, and nearly all of the available anti-depressants 
have deleterious side effects Which are attributable to a lack 
of speci?city, and/or cross-reactivity With regard to endog 
enous central nervous system processes. 
There is thus a need in the art for therapies to effectively 
treat psychopathologies, including, pain, hypophoria, drug 
abuse, depression, and the like, that are the result of excit 
able system disorders and abnormalities. 
2. Varied and Paradoxical Response to Psychoactive Drugs 
There is Wide heterogeneity of patients and their 
responses to psychoactive drugs used to treat pain and 
psychiatric diatheses. Patients suffering With chronic pain 
are often predisposed to depressive states Which result in 
disruption of lifestyle and frequently to use and abuse of 
drugs. 
Research in the past has implicated several chemically 
and functionally different excitable system neurochemical 
receptor systems in central analgesic processes Which are 
evocable and relieve certain painful conditions (i.e., nico 
tinic and muscarinic cholinergic, catecholamine, serotonin, 
enkephalins, dynorphins, NMDA and nitric oxide). 
Available scienti?c literature concerned With these pro 
cesses involved With one of the primary results of excitable 
system activity disorders, “pain,” can be summariZed as 
folloWs: First, there is duality of function (i.e., excitation vs. 






